Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis expands R&D in China

Sanofi-aventis has announced the establishment of a biometrics centre in Beijing as part of the expansion of its R&D facilities in China

Sanofi-aventis has announced the establishment of a biometrics centre in Beijing as part of the expansion of its R&D facilities in China.

The state-of-the-art centre will specialise in the design, data management and analysis of global and local trials, in both pharmaceuticals and vaccines development, through all four phases.

The French firm's partnership agreement with the Shanghai Institutes for Biological Sciences (SIBS) plays a key role in strengthening the company's R&D facilities. This partnership, which is part of the China Discovery platform set up by sanofi-aventis to build relationships with top Chinese academic institutions, aims to identify innovative, first-in-class drugs.

"This collaboration agreement brings pharmaceutical R&D in China to another level, by allowing talented Chinese scientists to become internationally recognised and ensuring that discoveries made in the area of basic research are rapidly converted into applications for treating diseases," said Dr Jia-Rui Wu, vice president of the SIBS.

Sanofi-aventis has also launched a scholarship programme in China to recognise promising scientists engaged in cutting-edge pharmaceutical R&D.

21st October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics